MESSINA, MONICA
 Distribuzione geografica
Continente #
NA - Nord America 93
EU - Europa 91
AS - Asia 13
AF - Africa 4
OC - Oceania 2
Totale 203
Nazione #
US - Stati Uniti d'America 92
IT - Italia 42
FR - Francia 20
DE - Germania 6
CZ - Repubblica Ceca 4
GB - Regno Unito 3
TR - Turchia 3
AU - Australia 2
CN - Cina 2
GR - Grecia 2
HK - Hong Kong 2
JP - Giappone 2
MK - Macedonia 2
NL - Olanda 2
RU - Federazione Russa 2
UA - Ucraina 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
BE - Belgio 1
BG - Bulgaria 1
CA - Canada 1
CM - Camerun 1
ES - Italia 1
FI - Finlandia 1
HU - Ungheria 1
IN - India 1
MY - Malesia 1
SA - Arabia Saudita 1
SE - Svezia 1
UG - Uganda 1
Totale 203
Città #
Rome 21
Ashburn 11
Santa Cruz 8
Buffalo 7
Des Moines 5
Fairfield 5
Seattle 5
Cambridge 4
Paris 4
Boardman 3
San Diego 3
Bremen 2
Houston 2
Istanbul 2
Kowloon 2
Las Vegas 2
Lodi 2
London 2
Los Angeles 2
Milan 2
Muizenberg 2
San Jose 2
Turin 2
Woodbridge 2
Barcelona 1
Beijing 1
Bergamo 1
Boydton 1
Brooklyn 1
Budapest 1
Cedar Knolls 1
Chicago 1
Ciciliano 1
Clearwater 1
Council Bluffs 1
Douala 1
Frankfurt am Main 1
Geel 1
Helsinki 1
Heraklion 1
Jersey City 1
Ladispoli 1
Lido di Ostia 1
Milwaukee 1
Nagoya 1
Naples 1
New York 1
Omaha 1
Petaling Jaya 1
Pontinia 1
Reston 1
Rho 1
Rimini 1
Riyadh 1
San Francisco 1
Sofia 1
Toronto 1
Vittuone 1
Washington 1
Wickliffe 1
Yalova 1
Totale 139
Nome #
Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances, file e3835326-a7a7-15e8-e053-a505fe0a3de9 91
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial, file e383532e-7042-15e8-e053-a505fe0a3de9 39
Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia, file e383532e-65c2-15e8-e053-a505fe0a3de9 31
The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials, file ff2154a0-495a-44a5-b8f2-85f75054a796 16
P523: The comparison of VFLAI, FLAI and 3 + 7 regimens by multilevel propensity score weighting highlights the benefit of the addition of venetoclax in no low risk aml treated in Gimema trials real world, file 8cedfab9-5b5e-4f5a-ac44-68017d4f6192 7
P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE, file 65f23933-9470-40d1-8143-b275f12570a8 6
null, file e383531e-4018-15e8-e053-a505fe0a3de9 5
Critical role of c-Myc in acute myeloid leukemia involving direct regulation of miR-26a and histone methyltransferase EZH2, file e3835312-12fc-15e8-e053-a505fe0a3de9 2
RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications, file e3835329-89e4-15e8-e053-a505fe0a3de9 2
Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223, file e3835311-c80a-15e8-e053-a505fe0a3de9 1
A case of late isolated ovarian relapse of acute lymphoblastic leukemia after an allogeneic stem cell transplant., file e3835322-2ad6-15e8-e053-a505fe0a3de9 1
Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia, file e3835329-89e5-15e8-e053-a505fe0a3de9 1
Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia, file e383532e-1af3-15e8-e053-a505fe0a3de9 1
Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996, file e383532e-6307-15e8-e053-a505fe0a3de9 1
Totale 204
Categoria #
all - tutte 611
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 611


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20193 0 0 0 0 0 0 0 0 0 0 0 3
2020/202125 2 3 3 1 0 0 3 2 3 0 1 7
2021/202246 1 1 0 3 3 1 0 1 1 13 18 4
2022/202365 10 8 7 9 3 4 4 3 2 0 9 6
2023/202462 1 6 6 1 14 7 9 10 0 8 0 0
Totale 204